<i>In vivo</i> reduction of amyloid-β by a mutant copper transporter

Amie L. Phinney(University Health Network), Bettina Drisaldi(University Health Network), Stephen D. Schmidt(University Health Network), Stan Lugowski(University Health Network), Veronica A. Coronado(University Health Network), Yan Liang(University Health Network), Patrick Horne(University Health Network), Jing Yang(University Health Network), Joannis Sekoulidis(University Health Network), Janaky Coomaraswamy(University Health Network), M. Azhar Chishti(University Health Network), Diane W. Cox(University Health Network), Paul M. Mathews(University Health Network), Ralph A. Nixon(University Health Network), George A. Carlson(University Health Network), Peter St George‐Hyslop(University Health Network), David Westaway(University Health Network)
Proceedings of the National Academy of Sciences
November 14, 2003
Cited by 202Open Access
Full Text

Abstract

Cu ions have been suggested to enhance the assembly and pathogenic potential of the Alzheimer's disease amyloid-beta (Abeta) peptide. To explore this relationship in vivo, toxic-milk (txJ) mice with a mutant ATPase7b transporter favoring elevated Cu levels were analyzed in combination with the transgenic (Tg) CRND8 amyloid precursor protein mice exhibiting robust Abeta deposition. Unexpectedly, TgCRND8 mice homozygous for the recessive txJ mutation examined at 6 months of age exhibited a reduced number of amyloid plaques and diminished plasma Abeta levels. In addition, homozygosity for txJ increased survival of young TgCRND8 mice and lowered endogenous CNS Abeta at times before detectable increases in Cu in the CNS. These data suggest that the beneficial effect of the txJ mutation on CNS Abeta burden may proceed by a previously undescribed mechanism, likely involving increased clearance of peripheral pools of Abeta peptide.


Related Papers